Synonyms: AC-430
Compound class:
Synthetic organic
Comment: AC430 is an investigational, potent and selective small molecule inhibitor of janus kinase 2 (JAK2) being developed by Ambit (now owned by Daiichi Sankyo) for the treatment of cancer and autoimmune diseases. AC430 is the (R) optical isomer claimed in patent US8703943 [1], although the (S) isomer and racemate are also discussed in the patent descriptions.
|
|
No information available. |
Summary of Clinical Use |
A Phase 1 safety and tolerability clinical study in healthy volunteers (NCT01287858) has been completed. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01287858 | Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects | Phase 1 Interventional | Daiichi Sankyo, Inc. |